deCODE genetics
  • HOME
  • COMPANY
    • ABOUT deCODE
    • MANAGEMENT
    • POLICIES
    • MEDIA RESOURCES
  • SCIENCE
  • PUBLICATIONS
  • NEWS
  • CAREERS
  • CONTACT
  • icelandic
Select Page

It’s Not Just the Sun: deCODE Discovers Sequence Variants Affecting Susceptibility to Skin Cancer

Jul 6, 2009 | NEWS

New risk factors for basal cell carcinoma that are independent of fair pigmentation; findings to be integrated into deCODEme™ and deCODEme Cancer™ scans Reykjavik, ICELAND, July 6, 2009 – Scientists at deCODE genetics (Nasdaq:DCGN) and academic colleagues from Europe...

Findings expand knowledge of the biology of the disease and provide potential new drug targets

Jul 1, 2009 | NEWS

Reykjavik, ICELAND, July 1, 2009 – The largest study of the genetics of schizophrenia ever undertaken has revealed several new common single-letter variants in the sequence of the human genome (SNPs) linked to risk of the disease. The study, by a multinational...

deCODE Discovers a Gene Linked to Risk of Kidney Stones and Osteoporosis

Jun 29, 2009 | NEWS

Findings offer promising target for drugs to better regulate calcium metabolism, are integrated into deCODEme™ Reykjavik, ICELAND, June 29, 2009 – A discovery by scientists at deCODE genetics (Nasdaq:DCGN) and academic colleagues from Iceland, the Netherlands and...

deCODE Genotyping Laboratory Receives College of American Pathologists Accreditation

May 20, 2009 | NEWS

Underscores quality of deCODE’s laboratory and tests, fulfilling key federal and state certification requirements and broadening marketing channels Reykjavik, ICELAND, May 20, 2009 – deCODE genetics (Nasdaq:DCGN) today announced that its CLIA-registered DNA isolation...

deCODE Study Shows Complex Interplay of the Human Biological Clock with Height, Weight and Disease

May 17, 2009 | NEWS

Reykjavik, ICELAND, May 17, 2009 – In a paper published today in the online edition of Nature Genetics, scientists from deCODE genetics (Nasdaq:DCGN) and academic colleagues from Iceland, Denmark and the Netherlands present the discovery of single letter variations in...

deCODE and Celera Partner to Expand Use of deCODE Risk Markers for Heart Attack, Stroke and Diabetes

Apr 23, 2009 | NEWS

Reykjavik, ICELAND, and Alameda, CA – April 23, 2009 – deCODE genetics (NASDAQ:DCGN) and Celera Corporation (NASDAQ:CRA) today announced the signing of agreements under which deCODE has granted Celera non-exclusive worldwide licenses to deCODE’s genetic markers...
« Older Entries
Next Entries »

MORE ABOUT DECODE

  • MANAGEMENT
  • POLICIES
  • CAREERS
  • AVAILABLE POSITIONS
  • CONTACT
  • NEWS

ABOUT deCODE

  • HOME
  • COMPANY
    • ABOUT deCODE
    • MANAGEMENT
    • POLICIES
    • MEDIA RESOURCES
  • SCIENCE
  • PUBLICATIONS
  • NEWS
  • CAREERS
  • CONTACT
  • icelandic

MANAGEMENT

  • MANAGEMENT
  • POLICIES
  • CAREERS
  • AVAILABLE POSITIONS
  • CONTACT
  • NEWS

LATEST NEWS

  • Amgen deCODE Genetics Takes Part in Its First Mission Week in Iceland
  • Running with Purpose: deCODE Team Joins Reykjavik Marathon to Make a Difference

ADDRESS

deCODE genetics
Sturlugata 8 | 101 Reykjavik
Iceland
Phone +354 570 1900

deCODE genetics | Sturlugata 8 | 101 Reykjavik | Iceland | phone +354 570 1900